Portuguese 
Spanish 
Polilaminin, a Brazilian innovation linked to UFRJ, reached 100 patients served by the Compassionate Use Program in Brazil, with progress reported in cases reassessed after 6 months, according to Só Notícia Boa, while the experimental treatment remains surrounded by expectation, medical caution, and regulatory evaluation.
Polilaminin reached the milestone of 100 patients served in Brazil through the Compassionate Use Program, according to a publication by Só Notícia Boa on July 8, 2026. The Brazilian experimental treatment is aimed at people with spinal cord injury and originates from research associated with UFRJ.
The milestone was announced by the team responsible for the program. According to Mitter Mayer, coordinator of the compassionate use working group for polilaminin, under the supervision of biologist Tatiana Sampaio, creator of the treatment at UFRJ, all patients reassessed after 6 months showed progress in the level of spinal cord injury.
Milestone of 100 patients expands the reach of Brazilian innovation
Reaching 100 patients puts polilaminin at a new level of visibility in Brazil. The information does not mean definitive approval as a widely available treatment, but it shows that the research has moved beyond just a laboratory promise and has begun to reach families in different Brazilian states through a specific route intended for exceptional situations.
-
Electrolux Unveils New Stove with Integrated Airfryer, PerfectCook360, VaporBake, Grill, Glass Top, and Oil-Free Large Portion Cooking
-
Brazil Approves Non-Hormonal Drug to Alleviate Menopausal Hot Flashes, Potentially Transforming Treatment
-
Giant Phantom Halo Appears Around Remote Pacific Islands, NASA Reveals It’s Created by Tiny Marine Organisms
-
Scientists Develop Method to Store Wind and Solar Energy by Liquefying Air for On-Demand Power Generation
The data also reinforces the weight of Brazilian science in this debate. A technology developed from the public university has entered the center of a medical race followed by patients, researchers, doctors, regulatory bodies, and families living with the impacts of spinal cord injury.
Compassionate use allows access before final approval
The service of the 100 patients occurred through the Compassionate Use Program, a mechanism that allows access to treatments not yet definitively approved in specific situations. According to the source, patients were served in different Brazilian states within a special protocol.
This point is important because it differentiates expectation from definitive proof. Polilaminin remains an experimental treatment, and compassionate use does not replace the necessary clinical trials to evaluate safety, dosage, application criteria, risks, and results under controlled conditions.
What the cases reassessed after 6 months indicate
According to Mitter Mayer, in an interview with Só Notícia Boa, all patients who received polilaminin and were reassessed after 6 months showed improvement in the level of spinal cord injury. The statement drew attention because it involves a significant milestone within the compassionate use program.
Even so, the stage of treatment itself requires careful interpretation. Improvement observed in patients followed by the program does not, by itself, mean that the substance can already be treated as a cure or guaranteed solution. The definitive answer depends on clinical evaluation, regulatory monitoring, and formal studies.
UFRJ, Tatiana Sampaio and Cristália appear at the center of research
Polilaminin is presented as a synthetic molecule derived from human laminin. The proposal, according to the source, is to act as a kind of biological structure capable of stimulating the regeneration of neurons in spinal cord injuries.
The development involves the Federal University of Rio de Janeiro, researcher Tatiana Sampaio, and the Cristália laboratory. The substance received authorization from Anvisa to begin Phase 1 clinical trials, a stage mainly focused on evaluating the safety of the experimental drug.
Acute spinal cord injury is the initial focus of the studies
The source informs that polilaminin has been studied for acute spinal cord injuries, especially traumas that occurred less than 72 hours ago. The application should occur quickly, before scar formation in the axons hinders the expected action of the drug.
This time window helps explain why the topic draws so much medical and family attention. In cases of spinal cord injury, the first hours can be decisive for clinical decisions, surgical referral, and evaluation of experimental alternatives available within sanitary rules.
Hope needs to walk together with medical caution
The arrival of polylaminin to 100 patients has symbolic impact for national science, but also demands responsibility in communication. The treatment is still under development and should not be presented as a ready answer for all cases of spinal cord injury.
At the same time, the brand shows that Brazil has the capability to produce cutting-edge research in an area of enormous complexity. The advancement involves innovation, public university, pharmaceutical industry, health regulation, and medical follow-up, not just a promising molecule.
How far can regeneration go?
The question involving polylaminin goes beyond the 100 patients treated: how far can regeneration go when science, medical structure, and national research advance together? For now, the answer still depends on studies, protocols, and regulatory evaluation.
The case, however, has already put Brazilian innovation in the spotlight. Do you believe that Brazil should accelerate investments in research like polylaminin, maintaining the caution of clinical trials, or should the priority be to first expand proof before any expansion? Leave your opinion in the comments.
